浙江省首个核酸药谷启动

Core Insights - Zhejiang's biopharmaceutical industry has reached a significant milestone with the unveiling of the "Hangzhou Nucleic Acid Drug Valley," marking a key step in establishing Hangzhou as a "Chinese Pharmaceutical Port" [1][2] - Nucleic acid-based drugs are recognized as a revolutionary third-generation therapy, showing breakthrough potential in treating major diseases such as tumors and genetic disorders [1] - The initial phase of the nucleic acid drug industry development plan has attracted over 30 leading enterprises and established various innovation and research facilities to support the full chain development of nucleic acid projects [1] Group 1 - The "Hangzhou Nucleic Acid Drug Valley" is located in Qiantang (New) District and is part of the broader initiative to create a comprehensive ecosystem for nucleic acid drug development [1] - The area has developed a complete closed-loop system from basic research to industrialization, featuring benchmark companies in research, diagnostics, and manufacturing [1][2] - The unveiling event included the establishment of the Nucleic Acid Drug Valley Innovation Transformation Research Institute and the signing of multiple key projects, enhancing the region's innovation capabilities [2] Group 2 - Qiantang District has laid out three functional platforms: a basic research platform, a transformation support platform, and an industrial support platform, to bolster the nucleic acid drug industry [2] - The establishment of a provincial innovation highland aims to propel Zhejiang's biopharmaceutical industry cluster to the international forefront [2] - The "Hangzhou Nucleic Acid Drug Valley" is expected to become a global core engine for nucleic acid drug innovation, contributing to the advancement of the biopharmaceutical industry [2]